86 related articles for article (PubMed ID: 12271586)
1. [Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)].
Vasil'ev IuV; Noskova KK; Zelenikin SA
Eksp Klin Gastroenterol; 2002; (1):55-60, 190. PubMed ID: 12271586
[TBL] [Abstract][Full Text] [Related]
2. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
[TBL] [Abstract][Full Text] [Related]
3. [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
Liu XH; Ke MY; Song ZQ; Luo JY; Yuan YZ; Hou XH; Zhu YL; Sun J; Zha H
Zhonghua Nei Ke Za Zhi; 2005 Nov; 44(11):818-21. PubMed ID: 16316559
[TBL] [Abstract][Full Text] [Related]
4. [Esophageal epithelial cells renewal in evaluation of the pariet efficacy in the treatment of patients with reflux esophagitis].
Osadchuk MA; Lipatova TE; Chaplygin NV
Eksp Klin Gastroenterol; 2002; (4):23-6, 131. PubMed ID: 12503269
[TBL] [Abstract][Full Text] [Related]
5. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
Archimandritis AJ; Nikolopoulou V; Kouklakis G; Paraskevas E; Avgerinos A; Tsianos E; Triantafillidis JK;
Curr Med Res Opin; 2005 Apr; 21(4):603-10. PubMed ID: 15899110
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
Maev IV; Kucheriavyĭ IuA; Danilin MS
Eksp Klin Gastroenterol; 2003; (5):10-2, 192. PubMed ID: 14621603
[TBL] [Abstract][Full Text] [Related]
7. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
Lim PW; Goh KL
J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
[TBL] [Abstract][Full Text] [Related]
8. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
[TBL] [Abstract][Full Text] [Related]
9. [Regeneration of the esophagus epitheliocytes. Evaluation of pariet efficacy in the treatment of patients with reflux esophagitis].
Osadchuk MA; Lipatova TE; Chaplygin NV
Eksp Klin Gastroenterol; 2002; (2):43-6, 102. PubMed ID: 12046386
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rabeprazole in gastroesophageal reflux disease: report of a multicenter study.
Kar P; Chandrashekar N; Devi S; Bhatia SJ; Alvares JF; Taneja A; Towar A
Indian J Gastroenterol; 2003; 22(4):153. PubMed ID: 12962446
[No Abstract] [Full Text] [Related]
11. [Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump].
Morozov SV; Tsodikova OM; Isakov VA; Tereshchenko SG; Gushchin AE; Shipulin GA
Ter Arkh; 2005; 77(2):21-5. PubMed ID: 15807445
[TBL] [Abstract][Full Text] [Related]
12. [Modern approach to the therapy of gastroesophageal reflux disease].
Ivashkin VT; Trukhmanov AS
Voen Med Zh; 2003 Oct; 324(10):26-34. PubMed ID: 14671892
[No Abstract] [Full Text] [Related]
13. [Rabeprazole test and comparison of the effectiveness of course treatment with rabeprazole in patients with gastroesophageal reflux disease and non-coronary chest pain].
Maev IV; Iurenev GL; Burkov SG; V'iuchnova ES
Klin Med (Mosk); 2007; 85(2):45-51. PubMed ID: 17520889
[TBL] [Abstract][Full Text] [Related]
14. [Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
Dtsch Med Wochenschr; 1998 Nov; 123(47 Suppl):1-4. PubMed ID: 9856116
[No Abstract] [Full Text] [Related]
15. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
16. Rabeprazole sodium.
Am J Health Syst Pharm; 1999 Nov; 56(22):2300. PubMed ID: 10582820
[No Abstract] [Full Text] [Related]
17. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Miner P
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():20-9. PubMed ID: 15496215
[TBL] [Abstract][Full Text] [Related]
18. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Hall J; Dodd S; Durkin M; Sloan S
Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
[TBL] [Abstract][Full Text] [Related]
19. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Caos A; Moskovitz M; Dayal Y; Perdomo C; Niecestro R; Barth J
Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
[TBL] [Abstract][Full Text] [Related]
20. [Some comparative aspects of treating the gastroesophageal reflux disease eradication].
Minushkin ON; Maslovskiĭ LV; Anikina NIu
Eksp Klin Gastroenterol; 2004; (3):45-8, 104. PubMed ID: 15560401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
